Navigation Links
Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
Date:4/8/2009

Reference

(1)Lutterbuese, R. et al. (2009). Potent control of tumor growth by CEA/CD3- bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. Journal of Immunotherapy, April 1, 2009 [epub ahead of print]

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell- destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. Typically antibodies cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. Previous attempts have shown the potential of T cells to treat cancer, but the therapeutic approaches tested to date have been hampered by cancer cells' ability to escape recognition by T cells. The use of BiTE antibodies that are specifically designed to engage T cells for attacking cancer cells may provide a more effective anti-tumor approach than conventional monoclonal antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treat
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
2. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
3. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
4. Genmab Announces HuMax-CD32b Pre-Clinical Program
5. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
6. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
7. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
8. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
9. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
10. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
11. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... GenomeDx Biosciences today announced that a new ... genomic test for prostate cancer, was able to predict ... radical prostatectomy without adjuvant therapy. Although rapid metastasis in ... tumor genomics to identify these men who have a ... advance. The study has been published online by ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... French engine electronics business , Milwaukee ... to Valeo, a French company that will pay approximately 330 ... is headquartered in Pontoise, France. Johnson Controls bought it in ... fiscal 2004 revenues at 350 million Euros. , SBC Foundation ...
... sciences professor at the University of Wisconsin-Madison, had seen his ... on the shelves. , ,Hed been working since the mid ... any of the businesses to which it had been licensed ... just been sitting there since about 1994 or 95," Cook ...
... havent had too much direct experience with really bad technology. ... confuses, yes, but really, really bad technology, on the scale ... tires? Not really. , ,Far more common is ... Were in a good organization, forward-looking, filling a niche ...
Cached Biology Technology:Scientist takes back patents and develops product others ignored 2Scientist takes back patents and develops product others ignored 3Why bad technology happens to good organizations 2Why bad technology happens to good organizations 3
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... at the edge of Alaska,s tundra are growing faster, suggesting ... rapidly warming climate, says a new study. While forests ... attributed to global warming, some white spruce trees in the ... last hundred years, especially since 1950, the study has found. ...
... bike path in Montana to a backwater underneath a ... June to capture high-resolution images for the first Nearby ... in their efforts to document global biodiversity as they ... week of Dec. 19-26., The GigaBlitz is organized ...
... University of Sheffield comparing rats and mice with their ... an important milestone in the evolution of mammals from ... tracking, the research team, which was led by Professor ... shed light on how rodents such as mice and ...
Cached Biology News:Trees on tundra's border are growing faster in a hotter climate 2Trees on tundra's border are growing faster in a hotter climate 3Trees on tundra's border are growing faster in a hotter climate 4GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 2GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 3Whiskers marked milestone in evolution of mammals from reptiles 2
Zonula Adherens Sampler Kit 10 mu g each...
Purified anti-SOCS3...
Tumor Suppressor Sampler Kit 10 mu g each...
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Biology Products: